COMPANY OVERVIEW

Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel orally-administered small-molecule therapeutics for the treatment of rare diseases.

---

LOCATION

New York, NY, USA

---

THERAPEUTIC AREAS

Rare Diseases

---

WEBSITE

https://attunepharma.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Jan 23, 2019

Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE

Jan 22, 2019

Attune Pharmaceuticals Announces Positive Phase 1 Results for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE

May 22, 2017

Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop

Mar 6, 2017

Attune Pharmaceuticals Announces Pre-Clinical Data for ATN-249, An Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at AAAAI

Mar 1, 2017

Attune Pharmaceuticals Announces Late-Breaking Poster Presentation of ATN-249, an Oral Kallikrein Inhibitor for the Treatment of HAE

For More Press Releases

---